Startup Behind Oxford-AstraZeneca Covid-19 Vaccine Files for U.S. IPO
April 09 2021 - 6:57PM
Dow Jones News
By Jenny Strasburg
LONDON -- The biotech startup behind the Covid-19 vaccine
jointly developed by AstraZeneca PLC and the University of Oxford
filed Friday with U.S. regulators for a public share offering.
Vaccitech PLC said in a securities filing it plans to use the
technology underpinning the vaccine to develop treatments targeting
prostate cancer, hepatitis B and human papillomavirus. The Wall
Street Journal reported Wednesday that the IPO filing could come as
soon as this week. The U.K.-based company plans to list on New
York's Nasdaq with the ticker symbol VACC.
(More to Come)
(END) Dow Jones Newswires
April 09, 2021 18:42 ET (22:42 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024